CONSORTIUM OF THE RECOMBINANT INFLUENZA A VIRUSES FLU-NS1-124- L7/L12-H5N1, FLU-NS1-124-OMP16-H5N1, FLU-NS1-124-L7/L12-H1N1 AND FLU-NS1- 124-OMP16-H1N1, FAMILY ORTOMYXOVIRIDAE, GENUS INFLUENZAVIRUS, EXPRESSING BRUCELLA IMMUNODOMINANT PROTEINS DESTINED TO GENERATE A VACCINE AGAINST BRUCELLOSIS

摘要

This invention relates to the fields of biotechnology, veterinary science and public health, and describes a vector vaccine which can be used to prevent brucellosis. The essence of the invention is that reverse genetics methods have been used to construct novel, genetically-stable recombinant influenza viral vectors based on the influenza A viral vectors Flu-NSl-124-L7/L12- H5N1, Flu-NSl-124-Omp16-H5Nl, Flu-NSl-124-L7/L12-HlNl and Flu-NSl-124-Omp16- H1N1 (of the subtypes H5N1 and H1N1) that contain the genetic sequences of the Brucella proteins L7/L12 (ribosomal) or Omp16 (outer membrane) inserted into the viral NS1 gene, which express these Brucella proteins in vivo and are safe in cattle. Our studies showed that this vaccine candidate in cattle induced a strong antigen-specific T-cell immune response, and most importantly provided a high level of protectiveness comparable to the commercial B. abortus S19 vaccine and superior to the B. abortus S19 vaccine in combination with Montanide Gel01 adjuvant. Furthermore it is shown that the developed vaccines can effectively differentiate vaccinated animals from infected animals.